TKT Awarded U.S. Patent Relating to Protein Production and Delivery For Gene Therapy
CAMBRIDGE, Mass., Oct 23, 2001 /PRNewswire via COMTEX/ -- Transkaryotic Therapies, Inc. (Nasdaq: TKTX chart, msgs) today announced that the U.S. Patent and Trademark Office has issued Patent No. 6,303,379 entitled, "In Vivo Protein Production and Delivery System for Gene Therapy." The patent covers the transfection of cells relating to the delivery of therapeutic proteins. This technology offers several advantages to conventional gene therapy approaches including safety, ease of administration, dose precision, and cost effectiveness.
"The issuance of this patent further strengthens TKT's intellectual property portfolio in the area of non-viral gene therapy," said Mary S. Consalvi, Vice President and Chief Intellectual Property Counsel at TKT. "Utilizing this novel technology, we have the potential to treat a variety of human diseases and conditions, among them anemia, diabetes, hemophilia, hypercholesterolemia, and multiple sclerosis, through the production and delivery of therapeutic proteins."
A copy of the patent described above is available on the World Wide Web at uspto.gov.
--- snipped --- |
